Valganciclovir for CMV in advanced HIV
Treatments studied
Part of Infections clinical trials.
This trial tests whether valganciclovir, an antiviral medicine, can help people with advanced HIV who have CMV in their blood but no CMV disease. The goal is to see if the medicine can reduce the amount of CMV and improve health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living with HIV and have a CD4 count of 100 or less (a very low immune system).
- You must have a positive blood test for CMV (cytomegalovirus), a common virus that can cause problems when immunity is weak.
- You must not have CMV disease in another part of your body, like your eyes (retinitis).
- You must be able to survive at least 48 hours and be expected to complete follow-up.
- You must not be pregnant or breastfeeding, and you must have adequate kidney and liver function.
- You must be able to swallow whole tablets and not have had a bad reaction to valganciclovir or similar drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
Hear when a new Cytomegalovirus (CMV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.